A Double-Blind, Placebo-conrolled, Parallel-group, Multicenter, Multiregional, One Year Study To Assess The Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn;s Disease
A study for patients with active moderate Crohn's Disease using study drug Rifaximin
Sponsor: Salix Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAP3200
U.S. Govt. ID: NCT02240121
Contact: Dania Lauer: 212-304-7256 / dl2908@columbia.edu
Additional Study Information: The purpose of the study is to determine if the experimental use of an antibiotic called rifaximin for upto one year can improve the symptoms of Crohns disease (like abdominalpain and liquid/very soft stools), and if rifaximin can improve the inflammation in the intestines causedby Crohns disease. The study is trying to determine if rifaximin, unlike other medicines forCrohns disease, can do these things by having an effect on the bacteria in the intestines, and if it canreduce disease processes that are causing inflammation in the intestines.
This study is closed
Simon Lichtiger, MD
Do You Qualify?
Have you been diagnosed with Celiac's disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Dania Lauer